RVTY US S&P 500Russell 1000 Earnings call · transcribed from the recording

Revvity (RVTY) · Q2 2026 results and valuation

Share price: $158.25 · 2026-11-11

Results Q2 2026 vs Q1 2026 · previous quarter · published 6 Aug 2026 and 5 May 2026

Net income up 27.3% on the previous quarter. Management sounded upbeat, in its script and in answers to analysts.

Only a basic analysis is available for this company at the moment.

1 · Numbers

+27.3%

Net income vs Q1 2026

Outlook given

Net income 51.8M vs 40.7M

Revenue +2.6%

Against the same quarter last year (Q2 2025) it is −3.9%, so the move on last quarter looks seasonal or timing-related rather than a trend.

2 · How management spoke

Upbeat

More upbeat than 65% of company calls

Answers to analysts: upbeat, in line with the script.

Similar to last call.

3 · What stood out

Guidance

Revvity still anticipates net interest and other expense to be approximately $90 million.

Valuation

Is Revvity undervalued?

Reverse DCF. Free cash flow from the last full fiscal year (2025-12-28), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.

At −4.8% growth a year (3-year revenue growth), the model's fair value is $14.14 a share — the stock trades 1019% above it. Today's price assumes 17.0% growth a year.

Current price

$158.25

close of 2026-11-11

Market implies growth of i

+17.0% for 10 yrs

Fair value / share

$14.14

Buy below

$10.60

Price vs fair value

Overvalued >200%

Price vs buy-below price

Overvalued >200%

FCF growth / yr i Discount rate i Terminal growth i Margin of safety i

Official channels

The company's own website and social media accounts.

Read between the lines

Key theme

While Revvity has touched on this over the past several quarters, demand for its high-content screening instruments, particularly its recently introduced new flagship instrument…

Source quote
“While we have touched on this over the past several quarters, demand for our high-content screening instruments, particularly our recently introduced new flagship instrument... ...and new demand from customers outside of our historical base contributed to a higher-than-normal level of instrument backlog exiting the second quarter, positioning us very well as we enter the second half of the year. Demand for high-content screening further accelerated...”
Guidance

As software returns to stronger growth in the second half of the year and as more of the instrument orders translate to revenue, Revvity expects to see improved performance...
Guidance

Revvity expects this to now result in its 2026 pro forma total revenue being in the range of $2.83 billion...
Fading

Revvity's adjusted operating margins came in at 23.6%, which was above its 23% outlook.

Source quote
“Our adjusted operating margins came in at 23.6%, which was above our 23% outlook. First, I'm really excited to report that Revvity delivered strong first quarter results with 3% total company organic growth, demonstrating the resilience and strength of our business. These results are a good start to the year and position us well to achieve our full year expectations, which Max will update you on in a bit.”

Tone

How upbeat the language was, compared with other companiesi. Dot: Q2 2026. Ring: Q1 2026.

Prepared remarks Upbeat (was typical)

Answers to analysts Upbeat (was typical)

Script and answers carried a similar tone, so the script's message held up under questioning.

Sentences that drove the tone

“Life Sciences Solutions grew low single digits organically in the quarter with both reagents and instrumentation growing in that range as stronger instrument performance was held back by timing of...”

“Our Diagnostic business performance remains robust and software continues to grow its annualized portfolio value in the double digits with a return to robust organic growth starting this quarter.”

“Reproductive health again grew in the mid-teens and immunodiagnostics growth outside of China accelerated into the high single digits, despite continued latent TB pressures.”

Full figures

USD · SEC EDGAR XBRL (10-Q, period end 2026-07-05)

Metric	Q2 2026period end 2026-07-05	Q1 2026period end 2026-04-05	Change	Q2 2025	YoY
Revenue	729.7M	711.1M	+2.6%	720.3M	+1.3%
Gross profit	416.9M	387.7M	+7.5%	392.6M	+6.2%
Operating income	89.3M	75.9M	+17.7%	90.8M	−1.6%
Net income	51.8M	40.7M	+27.3%	53.9M	−3.9%
EPS	0.47	0.36	+30.6%	0.46	+2.2%
P/E today 74.6	54.7	42.8	+11.9	41.6	+13.1

Topics

Most discussed now

These results reflect the continued strength and resilience of...
Revvity is clearly seeing improving momentum across the business, which is evident in both its performance in the quarter and...
As discussed, it is exciting to see tangible and accelerating signs of demand from customers tied to their increasing data...
Revvity continues to execute very well in the quarter from an operational standpoint as evidenced by its margin, earnings and...
To its traditional pharma biotech customers, Revvity is also now seeing orders coming directly tied to this AI...

Faded since Q1 2026

Dropped The transaction is anticipated to close by the end of next year, allowing time for the buyer to establish local...
Fading Operating margin standpoint
Dropped This is a bold decision and one that has a multitude of benefits for the company, including improved financial performance...
Fading I next want to highlight a transformative strategic decision Revvity has made that will accelerate its growth trajectory, improve its...

Latest announcements

Official filings, newest first.

2026-11-03 Results of operations; Other events · SEC 8-K
2026-08-04 Results of operations; Other events · SEC 8-K
2026-05-05 Results of operations; Other events · SEC 8-K
2026-05-01 Articles or bylaws amended; Shareholder vote results · SEC 8-K · routine
2026-02-02 Results of operations · SEC 8-K
2026-01-13 Results of operations; Regulation FD disclosure · SEC 8-K
2025-10-27 Results of operations · SEC 8-K
2025-10-24 Director or officer change · SEC 8-K